Drugs / potravitug
potravitug
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05769582 | Apr 2023 → Mar 2025 | polyomavirus infectious disease | Memo Therapeutics AG | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05358106 Comparator | May → Dec 2022 | BK-virus nephropathy | Memo Therapeutics AG | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | potravitug | “Antibody mAb 319C07 (USAN potravitug) neutralizes all four BK polyomavirus serotypes and recognizes an epitope critical for viral cell attachment.” PMID 40680077 ↗ Jul 2025 |
| Known as | 319C07 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068599 ↗ |
| Known as | 319CO7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068599 ↗ |
| Known as | AntiBKV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05358106 ↗ |
| Known as | mAb 319C07 | “Antibody mAb 319C07 (USAN potravitug) neutralizes all four BK polyomavirus serotypes and recognizes an epitope critical for viral cell attachment.” PMID 40680077 ↗ Jul 2025 |
| Known as | mAb129 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068599 ↗ |
| Modality | Protein / enzyme biologic | “a fully human highly neutralising antibody against BKV” NCT05358106 ↗ |
| Route | Intravenous | “administered as a single or multiple intravenous infusions” NCT05358106 ↗ |